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A B S T R A C T
The pharmacoresistance to antiepileptic drugs (AEDs) remains a major unsolved therapeutic need. The over-
expression of multidrug transporters, as the P-glycoprotein (P-gp), at the level of the blood-brain barrier of
epileptic patients has been suggested as a key mechanism underlying the refractory epilepsy. Thus, eﬀorts have
been made to search for therapeutically useful P-gp inhibitors. Herein, the strategy of ﬂavonoid/AED combined
therapy was exploited as a possible approach to overcome the P-gp-mediated pharmacoresistance. For this
purpose, several in vitro studies were performed using Madin-Darby canine kidney II (MDCK II) cells and those
transfected with the human multidrug resistance-1 (MDR1) gene, overexpressing the P-gp (MDCK-MDR1).
Overall, the results showed that baicalein, (−)-epigallocatechin gallate, kaempferol, quercetin and silymarin, at
200 μM, produced a marked increase on the intracellular accumulation of rhodamine 123 in MDCK-MDR1 cells,
potentially through inhibiting the P-gp activity. In addition, with the exception of lamotrigine, all other AEDs
tested (phenytoin, carbamazepine and oxcarbazepine) and their active metabolites (carbamazepine-10,11-ep-
oxide and licarbazepine) demonstrated to be P-gp substrates. Furthermore, the most promising ﬂavonoids as P-
gp inhibitors promoted a signiﬁcant increase on the intracellular accumulation of the AEDs (excluding lamo-
trigine) and their active metabolites in MDCK-MDR1 cells, evidencing to be important drug candidates to reverse
the AED-resistance. Thus, the co-administration of AEDs with baicalein, (−)-epigallocatechin gallate, kaemp-
ferol, quercetin and silymarin should continue to be explored as adjuvant therapy for refractory epilepsy.
List of chemical compounds studied in this article:
Baicalein (PubChem CID: 5,281,605); Carbamazepine (PubChem CID: 2554); Carbamazepine 10,11-epoxide
(PubChem CID: 2555); (−)-Epigallocatechin gallate (PubChem CID: 65064); Kaempferol (PubChem CID:
5280863); Lamotrigine (PubChem CID: 3878); Licarbazepine (PubChem CID: 114709); Oxcarbazepine
(PubChem CID: 34312); Phenytoin (PubChem CID: 1775); Silymarin (PubChem CID: 7073228); Quercetin
(PubChem CID: 5280343); Verapamil (PubChem CID: 2520).
1. Introduction
Despite the clinical availability of more than twenty antiepileptic
drugs (AEDs) with diﬀerent pharmacokinetic proﬁles, mechanisms of
action and potential for drug interactions, the development of drug-
resistant epilepsy remains as a major unresolved problem, aﬀecting
30–40% of patients (Baulac et al., 2015; Franco, French, & Perucca,
2016; Ventola, 2014). Although several pathomechanisms have been
advocated to explain the drug resistance to AEDs, two major hypotheses
have gained emphasis: the target hypothesis and the multidrug trans-
porter hypothesis (Löscher, Klitgaard, Twyman, & Schmidt, 2013;
Rogawski, 2013; Wang, Wang, Liu, &Ma, 2016). The former postulates
that AEDs lose eﬃcacy due to changes in the structure/functionality of
their target ion channels and neurotransmitter receptors; while the
multidrug transporter hypothesis suggests an overexpression of multi-
drug eﬄux transporters such as P-glycoprotein (P-gp) in brain capillary
endothelial cells, restricting AEDs penetration into the brain tissue of
non-responsive epileptic patients (Ferreira, Pousinho, Fortuna,
Falcão, & Alves, 2015; Gidal, 2014; Xiong, Mao, & Liu, 2015). This hy-
pothesis has been supported by important clinical ﬁndings that de-
monstrated a greater expression of P-gp in patients with recurrent sei-
zures (drug-resistant patients) than in those who have been seizure-free
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(Kwan et al., 2010b; Dombrowski et al., 2001; Jóźwiak, 2007; Marchi
et al., 2004). Similar evidence has also been obtained from several
animal models (Bartmann et al., 2010; Bauer et al., 2008; Liu, Yang,
Yang, & Yang, 2007; Marchi et al., 2006; Nishimura, Honda, Sugioka,
Takada, & Shibata, 2008). Furthermore, there are case reports of pa-
tients with drug-resistant epilepsy in which verapamil, a classic P-gp
inhibitor, was successfully used as an add-on agent to conventional AED
therapy, suggesting that P-gp inhibition could be one of the reasons
underlying the improved seizure control (Iannetti, Spalice, & Parisi,
2005; Summers, Moore, &McAuley, 2004).
Thus, the multidrug transporter hypothesis has become particularly
plausible in the context of drug-resistant epilepsy given that, similarly
to other drug classes, several AEDs have been found to be substrates of
the P-gp eﬄux pump (Luna-Tortós, Fedrowitz, & Löscher, 2008;
Stouch & Gudmundsson, 2002; Weiss, Kerpen, Lindenmaier,
Dormann, & Haefeli, 2003). Additionally, the exposure to certain AEDs
seems to cause the P-gp upregulation; actually, some AEDs have been
identiﬁed as P-gp inducers in both in vitro and in vivo conditions (Zhang,
Kwan, Zuo, & Baum, 2012).
Given the relevance of the aforementioned P-gp–mediated multidrug
resistance, eﬀorts have been made to search for therapeutically useful P-
gp inhibitors in order to overcome this functional barrier and reach
higher drug concentrations into the target tissue (Chen et al., 2016).
Nowadays, it is widely recognised the limited therapeutic success of ﬁrst-
and second-generation P-gp inhibitors, particularly due to their low po-
tency, aﬃnity and selectivity, requiring so high concentrations to inhibit
P-gp that severe toxic eﬀects are developed, compromising their clinical
use (Bansal, Jaggi, Khar, & Talegaonkar, 2009; Palmeira, Sousa,
Vasconcelos, & Pinto, 2012). In turn, the search for non-toxic third-gen-
eration P-gp inhibitors, which include herbal constituents like ﬂavonoids,
has gained a great attention (Bansal et al., 2009; Bansal, Awasthi, Jaggi,
Khar, & Talegaonkar, 2008; Ferreira et al., 2015). As several ﬂavonoids
share some of the properties of an ideal P-gp inhibitor, their interest as P-
gp modulators has increased in the last decade (Abdallah, Al-Abd, El-
Dine, & El-Halawany, 2015; Ferreira et al., 2015; Mohana et al., 2016).
As a result, compounds of this large group of polyphenolic constituents
have exhibited P-gp inhibitory eﬀects comparable to those of the classic
P-gp inhibitors (verapamil and cyclosporine A) (Bansal et al., 2009;
Ferreira et al., 2015; Schinkel & Jonker, 2012). In fact, some evidence of
the potential of ﬂavonoid compounds as P-gp inhibitors is supported by
in vitro and in vivo studies as reviewed by Ferreira et al. (2015).
Hence, aware that the P-gp overexpression can be induced by sei-
zures activity and chronic AED therapy, together with the fact that
several AEDs are P-gp substrates, is of paramount importance the
evaluation of the eﬀect of multiple ﬂavonoids on the activity of P-gp
eﬄux pump and their inﬂuence on AEDs transport. In fact, the number
of studies focusing on the eﬀect of ﬂavonoids in the disposition of
central nervous system-acting drugs, including AEDs, is scarce; never-
theless, the inhibition of P-gp has previously demonstrated to restore
the AEDs anticonvulsant activity in several animal models of refractory
epilepsy (Brandt, Bethmann, Gastens, & Löscher, 2006; Clinckers,
Smolders, Meurs, Ebinger, &Michotte, 2005; Höcht et al., 2007).
Therefore, for this purpose, Madin-Darby canine kidney cell line
transfected with the human multidrug resistance-1 (MDR1; ABCB1)
gene encoding P-gp (MDCK-MDR1) and its respective wild-type Madin-
Darby canine kidney II (MDCK II) cells were used to identify P-gp in-
hibitors among several ﬂavonoids and evaluate their eﬀects on the cell
uptake of AEDs and their active metabolites. In parallel, P-gp substrates
were identiﬁed among these drugs as well as their ability to interfere
with the P-gp activity. The compounds under investigation included
ﬂavonoids as apigenin, baicalein, (+)-catechin, (−)-epicatechin,
(−)-epigallocatechin gallate, ﬁsetin, hesperetin, kaempferol, naringin,
quercetin and silymarin, and some of the most commonly prescribed
AEDs [carbamazepine (CBZ), phenytoin (PHT), oxcarbazepine (OXC)
and lamotrigine (LTG)] and their pharmacologically active metabolites
[carbamazepine-10,11-epoxide (CBZ-E) and licarbazepine (LIC)].
2. Material and methods
2.1. Compounds and reagents
CBZ, CBZ-E, PHT, OXC, baicalein, (+)-catechin hydrate, ﬁsetin,
quercetin, silymarin, verapamil (a reference P-gp inhibitor used as
positive control), rhodamine 123 (Rh123; a P-gp ﬂuorescent probe
substrate) and primidone (used as internal standard in chromatographic
analysis) were all purchased from Sigma–Aldrich (St Louis, MO, USA).
Silymarin is composed of silybinin, silydianin and silychristin, and the
molar concentration was calculated based on the molecular weight of
silybinin because this is the main ﬂavonoid component present
(Zhang &Morris, 2003a, 2003b). Apigenin, (−)-epigallocatechin gal-
late, kaempferol, hesperetin and naringin were obtained from Santa
Cruz Biotechnology (Texas, USA) and (−)-epicatechin from Fluka (St
Louis, MO, USA). LIC was supplied by Tocris Bioscience (Bristol, UK)
and LTG was gently provided by Bluepharma (Coimbra, Portugal). All
cell culture reagents including Dulbecco's Modiﬁed Eagle's Medium -
high glucose (DMEM), fetal bovine serum (FBS), penicillin, strepto-
mycin, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphbenyltetrazolium bromide
(MTT), dimethyl sulfoxide (DMSO), trypsin-EDTA (0.5 g/L porcine
trypsin, 0.2 g/L EDTA) and phosphate-buﬀered saline (PBS) were ac-
quired from Sigma-Aldrich (St Louis, MO, USA). Methanol and acet-
onitrile, both of high-performance liquid chromatography (HPLC) gra-
dient grade, and ethyl acetate were purchased from Fisher Scientiﬁc
(Leicestershire, United Kingdom). Ultra-pure water (HPLC grade,>
18 MΩ·cm) was prepared by means of a Milli-Q water apparatus from
Millipore (Milford, MA, USA).
2.2. Cell lines and culture conditions
MDCK II (passages 8–10) and MDCK-MDR1 (passages 18–30) cells,
originally obtained from The Netherlands Cancer Institute (NKI-AVL;
Amsterdam, Netherlands), were cultured in 75-cm2 culture ﬂasks in
DMEM supplemented with 10% FBS, 100 IU/mL of penicillin and
100 μg/mL of streptomycin. The cell lines were maintained at 37 °C in a
humidiﬁed air incubator with 5% CO2 and the medium was renewed
every 2–3 days. Cells were seeded (density of 7.9 × 104 cells/cm2) in
96-well plates for cytotoxicity and Rh123 accumulation assays and in
24-well plates for the AEDs/metabolites accumulation assays. In both
cases the cells were maintained in culture for 4 days at 37 °C in an at-
mosphere of 5% CO2 before being subjected to the experiments.
2.3. Cytotoxicity assays
The in vitro cell viability was determined by the MTT assay ac-
cording to the procedure described by Freshney, 2010. Combination of
each ﬂavonoid (50–200 μM), verapamil (50 μM) or AED/metabolite
[CBZ (20–50 μM), CBZ-E (2–16 μM), PHT (40–75 μM), OXC (2–20 μM),
LIC (16–140 μM), LTG (12–55 μM)] with Rh123 (5 μM) were evaluated
as well as each AED/metabolite alone (at the highest concentration
level of the previously mentioned ranges) and their combination with
baicalein, (−)-epigallocatechin gallate, kaempferol, quercetin and si-
lymarin at 200 μM or verapamil (50 μM, positive control). The range of
AEDs/metabolites concentrations tested correspond to the values of
their therapeutic ranges (Hoyland, Hoy, Austin, &Wildman, 2013;
Patsalos et al., 2008).
Brieﬂy, cells were incubated for 4 h with the compounds of interest
at the designated concentration levels prepared in FBS-free DMEM
medium (1% DMSO, v/v). In the untreated control cells FBS-free DMEM
medium with the same ﬁnal concentration of DMSO (1%, v/v) was
used. After incubation the well-content was removed and 100 μL of
FBS- and antibiotic-free DMEM medium containing MTT (1 mg/mL)
was loaded to each well, followed by a new incubation step for 3 h
under the same conditions. Thereafter, the MTT-containing medium
was removed and replaced with DMSO to dissolve the formazan
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crystals. Afterwards, the content of the wells was transferred to a
reading 96-well plate and the absorbance was measured at 570 nm
using a microplate spectrophotometer xMark™ (Bio-Rad). Cell viability
was expressed as a percentage relatively to the absorbance determined
in the untreated control cells.
2.4. Intracellular rhodamine 123 accumulation assays
To identify the ﬂavonoid compounds that are P-gp inhibitors and
the AEDs/metabolites that are inducers of the P-gp activity, in-
tracellular accumulation assays of Rh123 were performed according to
Barthomeuf et al. (2005) with some modiﬁcations. At conﬂuence,
MDCK-MDR1 cells were washed once with PBS (pH 7.4) at 37 °C and
pre-incubated for 30 min with FBS-free DMEM medium containing the
test compounds as described in the following Sections 2.4.1 and 2.4.2.
Subsequently, 5 μM Rh123, prepared in FBS-free DMEM medium (1%
DMSO, v/v), was added to each well and the cells were maintained at
37 °C/5% CO2 for 2 h. These conditions were common through all
studies. Finally, cells were washed with cold PBS in order to stop the
accumulation of Rh123, and then lysed with 100 μL 0.1% Triton X-100
for 30 min at room temperature, protected from light. The ﬂuorescence
of cell lysates was measured with a SpectraMax Gemini spectro-
ﬂuorometer (Molecular Devices) at excitation/emission wavelengths of
485 nm/538 nm. Untreated control cells, exposed only to the drugs
vehicle [FBS-free DMEM medium containing DMSO (1%, v/v)], were
also incubated with 5 μM Rh123 in order to estimate the basal levels of
intracellular accumulation of Rh123. A Rh123 standard curve
(0.003125–5 μM) was generated to quantify the total amount of Rh123
accumulated in each sample.
2.4.1. Identiﬁcation of ﬂavonoid compounds as P-glycoprotein inhibitors
MDCK-MDR1 cells were pre-incubated for 30 min with FBS-free
DMEM medium containing apigenin, baicalein, (+)-catechin,
(−)-epicatechin, (−)-epigallocatechin gallate, ﬁsetin, hesperetin,
kaempferol, naringin, quercetin or silymarin. The positive control
consisted of incubating the cells with verapamil instead of ﬂavonoid.
Flavonoid compounds were tested at 50, 100 and 200 μM, and ver-
apamil was incubated at 50 μM, and all were prepared in FBS-free
DMEM medium (1% DMSO, v/v).
2.4.2. Identiﬁcation of antiepileptic drugs/metabolites as inducers of P-
glycoprotein activity
MDCK-MDR1 cells were pre-incubated for 30 min with FBS-free
DMEM medium containing each AED or active metabolite. These
compounds were tested at three concentrations corresponding to the
low, medium and high level of their therapeutic ranges: 20, 30 and
50 μM for CBZ; 2, 8 and 16 μM for CBZ-E; 12, 65 and 140 μM for LIC;
12, 35 and 55 μM for LTG; 2, 10 and 20 μM for OXC; and 40, 55 and
75 μM for PHT.
2.5. Intracellular antiepileptic drugs accumulation assays
2.5.1. Identiﬁcation of antiepileptic drugs/metabolites as P-glycoprotein
substrates
Conﬂuent and washed MDCK II and MDCK-MDR1 cells were in-
cubated for 2 h with FBS-free DMEM medium containing each AED or
active metabolite. The AEDs and active metabolites were tested at
therapeutic concentrations (50 μM for CBZ, 16 μM for CBZ-E, 140 μM
for LIC, 55 μM for LTG, 20 μM for OXC and 75 μM for PHT) and pre-
pared in FBS-free DMEM (1% DMSO, v/v). After incubation, cells were
washed and lysed as described above in Section 2.4, and the content of
each well was individually collected and frozen at −20 °C until HPLC
analysis.
2.5.2. Eﬀects of ﬂavonoid compounds on the intracellular accumulation of
antiepileptic drugs/metabolites
The ﬂavonoids identiﬁed as P-gp inhibitors [baicalein, (−)-epi-
gallocatechin gallate, kaempferol, quercetin and silymarin] were se-
lected to evaluate their eﬀects on the intracellular accumulation of each
AED or active metabolite. For that, conﬂuent and washed MDCK-MDR1
cells were pre-incubated for 30 min with FBS-free DMEM medium, in
the presence of ﬂavonoids or the positive control (verapamil).
Flavonoids were tested at 200 μM and verapamil at 50 μM, and all were
prepared in FBS-free DMEM (1% DMSO, v/v). Untreated control cells
were exposed only to FBS-free DMEM with the same ﬁnal concentration
of DMSO (1%, v/v) in order to estimate the basal intracellular accu-
mulation of AED/metabolite. Then, untreated and P-gp inhibitor
treated cells were incubated with the AEDs or metabolites at the highest
tested concentration (CBZ 50 μM, CBZ-E 16 μM, LIC 140 μM, LTG
55 μM, OXC 20 μM and PHT 75 μM) for 2 h. Afterwards, cells were
washed and lysed as described above in Section 2.4, and the content of
each well was separately collected and frozen at −20 °C until HPLC
analysis.
2.6. HPLC analysis
The quantitative HPLC analysis of AEDs and their active metabo-
lites was performed based on the methods previous reported by
Ferreira, Rodrigues, Falcão, & Alves, 2016a, 2016b. For the determi-
nation of CBZ, CBZ-E, LIC, LTG and PHT in MDCK II or MDCK-MDR1
cell lysates, two HPLC methods were used. Brieﬂy, to each aliquot
(200 μL) of 0.1% Triton X-100 samples were added 20 μL of the in-
ternal standard working solution, 300 μL of acetonitrile and 1 mL of
ethyl acetate. The mixture was vortex-mixed for 30 s and centrifuged
at 13500 rpm (3 min). Then, the sample was re-extracted twice more
with ethyl acetate (1 mL each time) using the same conditions. The
whole organic extract was evaporated to dryness under a nitrogen
stream at 45 °C and then reconstituted with 100 μL of mobile phase.
An aliquot (20 μL) of this ﬁnal sample was injected into the HPLC
system.
Chromatographic analysis was carried out using an HPLC system
(Shimadzu LC-2010A HT Liquid Chromatography) coupled with a diode
array detector (Shimadzu SPD-M20A). All instrumental parts were au-
tomatically controlled by LabSolutions software (Shimadzu, Kyoto,
Japan). The chromatographic separation was carried out at 35 °C on a
reversed-phase LiChroCART® Purospher Star column (C18,
55 mm× 4 mm; 3 μm particle size) purchased from Merck KGaA
(Darmstadt, Germany). For the determination of CBZ, CBZ-E, OXC and
LIC an isocratic elution was applied at a ﬂow rate of 1.0 mL/min with a
mobile phase composed of water/methanol/acetonitrile (69:25:6, v/v/
v), and primidone was used as internal standard (working solution at
500 μg/mL). The wavelength of 215 nm was selected for detection of all
compounds. On the other hand, the chromatographic analysis of LTG
and PHT was carried out using an isocratic elution with acetonitrile
(6%), methanol (25%) and a mixture (69%) of water–triethylamine
(99.7:0.3, v/v; pH 6.0), pumped at 1 mL/min; in this case, CBZ was
used as internal standard (working solution at 200 μg/mL). The com-
pounds were detected at 215 nm (LTG and CBZ) and 235 nm (PHT).
The mobile phases were ﬁltered through a 0.2 μm ﬁlter and degassed
ultrasonically for 15 min before use and the injected sample volume
was always 20 μL.
2.7. Statistical analysis
Data were reported as mean ± standard error of the mean. The
statistical analysis was performed using GraphPad Prism 5.0 (GraphPad
Software, La Jolla, CA, USA). Whenever a simpler statistical analysis
was needed to evaluate the eﬀect of each treatment versus the control
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group, a one-way ANOVA with the post hoc Dunnett's test was con-
ducted. To check for statistically signiﬁcant diﬀerences not only with
the control group but also for comparing multiple treatments a one-way
ANOVA with the post hoc Tukey's test for multiple comparisons was
performed. In some speciﬁc cases, a Student's t-test was applied to
compare two groups. A diﬀerence was considered to be statistically
signiﬁcant for a p-value lower than 0.05 (p < 0.05). The statistical
tests used were appropriately identiﬁed in the ﬁgure legends.
Fig. 1. Cell viability data for ﬂavonoids (A-D), verapamil (D) and antiepileptic drugs or metabolites (E–F) together with 5 μM rhodamine123 (Rh123) after 4 h of incubation in MDCK-
MDR1 cells. Data are expressed as the mean ± standard error of the mean (n= 6). Multiple comparisons between treated cells vs. untreated control cells as well as among the diﬀerent
concentrations of ﬂavonoids or antiepileptics/metabolites were performed by one-way ANOVA with the post hoc Tukey's test (*p < 0.05). CBZ, carbamazepine; CBZ-E, carbamazepine-
10,11-epoxide; EPG, (−)-epigallocatechin gallate; LIC, licarbazepine; PHT, phenytoin.




The eﬀects of the diﬀerent combinations of each ﬂavonoid (or
verapamil) with Rh123 in cell viability was investigated during 4 h. As
shown in Fig. 1A–D, only a few concentrations of ﬂavonoids induced a
statistically signiﬁcant reduction of cell viability (p < 0.05) when
compared to untreated control cells [ﬁsetin, (+)-catechin and
(−)-epicatechin at 200 μM; and silymarin and (−)-epicatechin at
100 μM], but without a very marked eﬀect. It is worthy of note that the
cytotoxicity of verapamil at 50 μM (82.6%) was similar or higher than
that observed with the highest tested concentration of ﬂavonoids
(200 μM). In turn, baicalein did not reduce the cell viability, instead it
appeared to increase the cell proliferation at 200 μM (Fig. 1C).
Regarding the combination of AEDs or metabolites and Rh123 at
5 μM (Fig. 1E–F), statistically signiﬁcant diﬀerences in reduction of cell
viability were observed for OXC over the tested concentration range
(2–20 μM; p < 0.05) and also for LTG at the lower concentrations
assayed (12 and 35 μM; p < 0.05); however, cytotoxicity for LTG at
55 μM was not signiﬁcant. In addition, the eﬀects on the cell viability
produced by the diﬀerent concentrations of LTG and OXC were tested
by the one-way ANOVA with the post hoc Tukey's test and no statisti-
cally signiﬁcant diﬀerences were found (p > 0.05), supporting the use
of the highest concentration levels of both AEDs in the following in-
tracellular Rh123 accumulation assays.
Fig. 2 represents the data of cell viability obtained for each AED (or
metabolite) alone and in combination with each one of the selected
ﬂavonoid compounds or verapamil. Overall, the AED (or metabolite)/
ﬂavonoid combinations did not appear to produce important cytotoxic
eﬀects, which supports the use of these concentrations in the sub-
sequent studies. Once again, in general, no marked loss of cell viability
was induced by combinations of verapamil (50 μM) and AEDs or me-
tabolites.
3.2. Identiﬁcation of ﬂavonoid compounds as P-glycoprotein inhibitors
According to the results depicted in Fig. 3, ﬁve [baicalein,
(−)-epigallocatechin gallate, kaempferol, quercetin and silymarin] of
the eleven ﬂavonoids tested induced a marked increase on the in-
tracellular accumulation of Rh123 in MDCK-MDR1 cells. The results
obtained showed statistically signiﬁcant diﬀerences between ﬂavonoid
treated cells and untreated control cells (*p < 0.05) in almost all
tested concentrations, the last representing the basal intracellular ac-
cumulation of Rh123 (negative control). Moreover, as it can be seen in
Fig. 3, the eﬀects of baicalein, (−)-epigallocatechin gallate, kaemp-
ferol, quercetin and silymarin on the intracellular accumulation of
Rh123 occurred in a concentration-dependent manner (#p < 0.05).
Actually, the intracellular accumulation of Rh123 increases as the
concentration of these ﬁve ﬂavonoids increases (a predictive marker of
P-gp inhibition). Speciﬁcally, (−)-epigallocatechin gallate at 200 μM
produced an increase in the intracellular accumulation of Rh123 similar
to that exhibited by verapamil (positive control as P-gp inhibitor). On
the contrary, apigenin, (+)-catechin, (−)-epicatechin and ﬁsetin de-
creased the intracellular accumulation of Rh123, suggesting to be in-
ducer agents of the P-gp activity, whereas none eﬀect was found for
hesperetin and naringin.
Taking into account these results, baicalein, (−)-epigallocatechin
gallate, kaempferol, quercetin and silymarin at 200 μM were selected to
be evaluated in the subsequent experiments involving the combination
Fig. 2. Cell viability data for (A) carbamazepine (CBZ), (B) carbamazepine-10,11-epoxide (CBZ-E), (C) licarbazepine (LIC), (D) lamotrigine (LTG), (E) oxcarbazepine (OXC) and (F)
phenytoin (PHT) alone and together with verapamil or ﬂavonoids after 4 h of incubation in MDCK-MDR1 cells. Data are expressed as the mean values ± standard error of the mean
(n= 6). Comparisons between treated cells vs. untreated control cells were performed by one-way ANOVA with the post hoc Dunnett's test (⁎p < 0.05). EPG, (−)-epigallocatechin
gallate.
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with AEDs or their active metabolites.
3.3. Identiﬁcation of antiepileptic drugs/metabolites as inducers of P-
glycoprotein activity
Although with diﬀerent magnitudes and with the exception for CBZ
at 50 μM, CBZ-E (2, 8 and 16 μM) and OXC at 2 μM, a statistically
signiﬁcant decrease in the accumulation of Rh123 into MDCK-MDR1
cells was found for the AEDs or metabolites, appearing to exhibit an
inducer eﬀect on the P-gp activity (Fig. 4). Overall, it is noteworthy the
concentration-dependent eﬀect found for OXC on the intracellular ac-
cumulation of Rh123, which signiﬁcantly decreases as the concentra-
tion of OXC increases (#p < 0.05). In contrast to OXC, no statistically
signiﬁcant diﬀerence was detected among the diﬀerent concentrations
of the other AEDs or metabolites tested.
Fig. 3. Eﬀect of ﬂavonoids on the intracellular
accumulation of rhodamine 123 (Rh123) in
MDCK-MDR1 cells. The results were obtained by
comparing the ﬂavonoid (or verapamil) pre-
treated cells vs. untreated cells (control). Data are
expressed as the mean values ± standard error
of the mean (n= 6). The basal intracellular ac-
cumulation of Rh123 in the control group was
0.0097 ± 0.0026 μM. Multiple comparisons be-
tween ﬂavonoids/verapamil group vs. control
group (⁎p < 0.05) as well as among the diﬀerent
concentrations of ﬂavonoids (#p < 0.05) were
performed by one-way ANOVA with the post hoc
Tukey's test. (−)-EPG, (−)-epigallocatechin gal-
late.
Fig. 4. Identiﬁcation of P-glycoprotein inducers among the
antiepileptics/metabolites through rhodamine 123 (Rh123)
accumulation assays performed in MDCK-MDR1 cells. The
results were obtained by comparing the intracellular accu-
mulation of Rh123 in antiepileptics or metabolites pre-
treated cells vs. untreated cells (control). Data are expressed
as the mean values ± standard error of the mean (n= 6).
The basal intracellular accumulation of Rh123 in the con-
trol group was 0.0091 ± 0.0016 μM. Multiple compar-
isons between antiepileptics/metabolite group vs. control
group (⁎p < 0.05) as well as among the diﬀerent con-
centrations of antiepileptics/metabolites (#p < 0.05) were
performed by one-way ANOVA with the post hoc Tukey's
test. CBZ, carbamazepine; CBZ-E, carbamazepine-10,11-
epoxide; EPG, (−)-epigallocatechin gallate; LIC, licarbaze-
pine; LTG, lamotrigine; OXC, oxcarbazepine; PHT, pheny-
toin.
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3.4. Identiﬁcation of antiepileptic drugs/metabolites as P-glycoprotein
substrates
The intracellular accumulation of the AEDs or metabolites was
evaluated and compared in both MDCK II cells and MDCK-MDR1 cells.
Taking into account the results presented in Fig. 5, the intracellular
accumulation of CBZ (p= 0.0011), CBZ-E (p= 0.0254), LIC
(p= 0.0060) and PHT (p= 0.0071) was 1.2 to 1.5 times higher in
MDCK II than in MDCK-MDR1 cells. Nevertheless, the degree of in-
tracellular accumulation of OXC was very much steeper in MDCK II (a
16-fold increase) than in MDCK-MDR1 cells (p= 0.0003). On the
contrary, no relevant diﬀerences were observed in the intracellular
accumulation of LTG between the two cell lines. Contrarily to the LTG,
the lower intracellular accumulation of CBZ, CBZ-E, LIC, OXC and PHT
in the MDCK-MDR1 cells than in MDCK II cells indicates that these
AEDs and metabolites are P-gp substrates in this cell model.
3.5. Eﬀects of ﬂavonoid compounds on the intracellular accumulation of
antiepileptic drugs/metabolites
According to the results shown in Fig. 6, the majority of ﬂavonoids
signiﬁcantly increased the intracellular accumulation of the AEDs and
their active metabolites in MDCK-MDR1 cells comparatively to the
untreated control cells (p < 0.05). LTG was the unique AED whose
intracellular accumulation was not aﬀected by any of the tested ﬂa-
vonoids (Fig. 6D). Overall, silymarin was the ﬂavonoid compound that
most increased the AED or metabolite accumulation, suggesting to be
the most promising ﬂavonoid as P-gp inhibitor. Actually, in some of the
cases, the eﬀect of silymarin on the intracellular accumulation of AEDs/
metabolites was very close to that produced by verapamil. In opposi-
tion, kaempferol was the ﬂavonoid that less increased the intracellular
accumulation of AEDs or metabolites.
4. Discussion
The search for new therapeutic options continues to be pursued in
order to overpass the pharmacoresistance in epilepsy. The recognition
of P-gp-mediated drug eﬄux as a major factor responsible for drug
resistance that may restrict the penetration or accumulation of AEDs
into the epileptic brain tissue has increased the demand for P-gp in-
hibitors that could enhance the AEDs concentration in the site of action
(Löscher et al., 2013; Robey, Lazarowski, & Bates, 2008; Zhang et al.,
2012). These eﬀorts are particularly justiﬁed by the fact that this gly-
coprotein is overexpressed in patients with the phenotype of drug-re-
sistant epilepsy, who are resistant to several, if not all, AEDs despite
their diﬀerent mechanisms of action. Moreover, evidence has been re-
ported supporting the inducer eﬀects of AEDs on the P-gp activity. All
these ﬁndings support the transporter hypothesis of AED-resistant epi-
lepsy and emphasize the potential of P-gp inhibitors in an attempt to
reverse this drug resistance phenomenon (Gidal, 2014; Luna-Tortós
et al., 2008; Zhang et al., 2012).
Bearing in mind this possible therapeutic approach, the current
study had as a starting point the evaluation of the potential of a series of
ﬂavonoids to inhibit the P-gp. The selection of these ﬂavonoid
Fig. 5. Comparison of the intracellular accumulation of antiepileptic drugs/metabolites between MDCK II and MDCK-MDR1 cells. Data are expressed as the mean values ± standard
error of the mean (n= 3). Comparisons between MDCK II vs. MDCK-MDR1 group were performed by Student's t-test. ⁎p < 0.05, compared to control group (MDCK II cell line).
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compounds was based on an extensive literature review within this
scope conducted by Ferreira et al. (2015). Moreover, as our main focus
was the improvement of the epilepsy treatment, whenever possible a
particular attention was given to ﬂavonoid compounds with intrinsic
anticonvulsant properties, aiming to ﬁnd promising compounds po-
tentially with dual and complementary mechanisms of action. Ac-
cording to our results, ﬁve ﬂavonoids [baicalein, (−)-epigallocatechin
gallate, kaempferol, quercetin and silymarin] were identiﬁed as pro-
mising P-gp inhibitors due to their ability to increase the intracellular
accumulation of Rh123 in MDCK-MDR1 cells. Although we expected to
ﬁnd some ﬂavonoid compounds capable of inhibiting P-gp, the increase
on the intracellular accumulation of Rh123 promoted by (−)-epi-
gallocatechin gallate at 200 μM was truly remarkable (a 16-fold in-
crease), being similar to that found with verapamil, a standard P-gp
inhibitor (Fig. 3).
The exact mechanisms underlying ﬂavonoid–P-gp interactions are
not yet clear. Nevertheless, several hypotheses have been proposed: (1)
ﬂavonoids can directly bind to the C-terminal nucleotide-binding do-
main of P-gp (NBD2) and modulate P-gp by interacting in a bifunctional
way with the vicinal ATP-binding site and the steroid binding site
within a cytosolic domain of P-gp (chrysin, ﬂavone, quercetin, rutin,
apigenin, 3-hydroxyﬂavone, genistein, kaempferide, and kaempferol)
(Conseil et al., 1998); (2) ﬂavonoids can act as substrate and may di-
rectly interact with P-gp either by competitive binding to the substrate-
binding site or by binding to other drug-binding sites and changing the
P-gp conformation (genistein, epicatechin gallate, catechin gallate,
epigallocatechin gallate and silymarin) (Castro & Altenberg, 1997;
Jodoin, Demeule, & Beliveau, 2002; Shapiro & Ling, 1997;
Zhang &Morris, 2003a); and (3) ﬂavonoids may bind to an allosteric
site (epicatechin) (Wang, Barecki-Roach, & Johnson, 2002). It is worthy
to mention that in our studies the inhibitory activity of baicalein,
(−)-epigallocatechin gallate, kaempferol, quercetin and silymarin ap-
peared to be concentration-dependent, increasing with ﬂavonoids
concentrations. These results are in accordance with the literature
(Ferreira et al., 2015).
In addition, other pharmacological properties that have been ex-
hibited by ﬂavonoid compounds can also contribute to enhance the
interest in these agents to reverse the AED-resistant epilepsy. Indeed,
the potential of ﬂavonoids as antiepileptic/anticonvulsant drugs has
been widely debated. For instance, baicalein (Yoon et al., 2011) and
quercetin (Baluchnejadmojarad, Roghani, & Homayounfar, 2010;
Nassiri-Asl et al., 2013, 2014) demonstrated some anticonvulsant ac-
tivity in rodent models of acute and chronic seizures. Furthermore, the
therapeutic potential of ﬂavonoid compounds for frequent epilepsy
comorbidities, due to their activity on cognition and neurodegenera-
tion, inﬂammation and depression, emphasizes, even more, the interest
in these multi-target compounds for complex central nervous system
(CNS) disorders such as epilepsy. Particularly, quercetin demonstrated
to have neuroprotective eﬀects on hippocampal injury post status epi-
lepticus (Hu et al., 2011), whereas baicalein evidenced a protective role
against global ischemia (Romano et al., 2013). Moreover, quercetin
demonstrated to inhibit both cyclooxygenase and lipoxygenase activ-
ities, diminishing the formation of inﬂammatory mediators. Ad-
ditionally, ﬂavonoids appear to inhibit eicosanoid biosynthesis and
neutrophil degranulation (Nijveldt et al., 2001). Some ﬂavonoids like
quercetin and kaempferol also revealed antidepressant activity through
their eﬀects by the stimulation of brain-derived neurotrophic factor and
the reduction of amyloid-beta peptide toxicity (Hou et al., 2010).
Although there are studies reporting some AEDs as P-gp substrates,
this point was also herein investigated using MDCK II and MDCK-MDR1
cells, because there is still no consensus on this subject (Zhang et al.,
2012). Taking into account our results, only the LTG did not demonstrate
to be a P-gp substrate in the MDCK-MDR1 cell model; in contrast, OXC
appears to have been subjected to a strong eﬄux transport mediated by
P-gp (Fig. 5). According to the results of other in vitro and in vivo studies,
including clinical trials, AEDs as LTG, PHT and OXC are classiﬁed as
Fig. 6. Eﬀect of selected ﬂavonoid compounds or verapamil in the intracellular accumulation of (A) carbamazepine (CBZ), (B) carbamazepine-10,11-epoxide (CBZ-E), (C) licarbazepine
(LIC), (D) lamotrigine (LTG), (E) oxcarbazepine (OXC) and (F) phenytoin (PHT) in MDCK-MDR1 cells. Data are expressed as the mean values ± standard error of the mean (n= 3).
Comparisons between ﬂavonoids and verapamil groups vs. control (basal drug accumulation) group were performed by one-way ANOVA with the post hoc Dunnett's test. ⁎p < 0.05,
compared to control group. EPG, (−)-epigallocatechin gallate.
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deﬁnitive P-gp substrates, while CBZ, CBZ-E and S-LIC are classiﬁed only
as probable P-gp substrates as deeply reviewed by Zhang et al. (2012).
The main divergence between our results and those of the literature in-
volves the LTG, which has not yet been investigated in MDCK-MDR1
cells; however, LTG was found to be a P-gp substrate in LLC-PK1 cells
transfected with human MDR1 and in OS2.4/Doxo cells, but not in the
Caco-2 cell line (Zhang et al., 2012). According to an in vitro transpor-
tation study performed by Zhang, Zuo, Kwan, and Baum (2011), CBZ
analogues (eslicarbazepine acetate, OXC, S-LIC and CBZ-E) were found to
be P-gp substrates. Indeed, there are few in vitro studies in the literature
evaluating OXC as P-gp substrate but, in this particular one, OXC ex-
hibited a higher rate of P-gp-mediated eﬄux transport than its deriva-
tives (except for the eslicarbazepine acetate) (Zhang et al., 2011). Despite
the availability of some studies that evaluated the structure-activity re-
lationship of multiple P-gp substrates (Ekins et al., 2002; Raub, 2006;
Wang, Kuo, Lien, & Lien, 2003), the reports analysing the structure-ac-
tivity relationship regarding the interactions between AEDs and P-gp are
limited (Knight &Weaver, 1998). Nevertheless, CBZ and its analogues
have the identical dibenzazepine (iminostilbene) nucleus, diﬀering at the
10,11-position; this planar structure has been reported to be very im-
portant for the interaction with P-gp (Ferreira et al., 2015). Conse-
quently, the ketone group exhibited by OXC at the 10,11-position can be
responsible for the higher aﬃnity for P-gp evidenced by OXC when
compared to CBZ and its structural analogues (Fig. 5).
After identifying the most promising ﬂavonoids as P-gp inhibitors,
and classifying the AEDs and their active metabolites as P-gp substrates
or not in MDCK-MDR1 cells, the potential of the promising ﬂavonoids
[baicalein, (−)-epigallocatechin gallate, kaempferol, quercetin and si-
lymarin] to promote the intracellular accumulation of the AEDs was
also assessed. Although with diﬀerent degrees of potency, almost all the
selected ﬂavonoids demonstrated to enhance the intracellular accu-
mulation of AEDs or their active metabolites into MDCK-MDR1 cells. As
expected, only the intracellular accumulation of LTG was not changed
in the presence of ﬂavonoids once it did not appear to be a P-gp sub-
strate in the MDCK-MDR1 cells (Fig. 6D). The remarkable eﬀect pro-
duced by tested ﬂavonoids and verapamil on the intracellular accu-
mulation of OXC is in accordance with its proﬁle as P-gp substrate.
Moreover, we have recently demonstrated in an exploratory study
conducted in Wistar rats that silymarin and (−)-epigallocatechin gal-
late increase the systemic and brain exposure to OXC and its active
metabolite LIC. More speciﬁcally, the pre-treatment of rats with sily-
marin and (−)-epigallocatechin gallate combinations originated peak
plasma concentrations of OXC and LIC similar to those achieved in the
presence of verapamil (positive control); additionally, the eﬀects pro-
moted by silymarin/(−)-epigallocatechin gallate combinations on the
magnitude of systemic drug exposure to OXC and LIC were also re-
ﬂected in the corresponding drug levels attained in the brain (biophase)
(Ferreira, Rodrigues, Marques, Falcão, & Alves, 2017). Actually, other
studies have also demonstrated that the huge diﬀerences observed in
the transportation of OXC in MDCK and LLC MDR1-transfected versus
non-transfected cells were almost completely abolished by verapamil
and tariquidar, both P-gp inhibitors (Zhang et al., 2011). Indeed, the
positive eﬀect of verapamil on the OXC bioavailability was even re-
ported in healthy volunteers (Antunes et al., 2016).
Furthermore, the set of tested ﬂavonoid compounds did not seem to
importantly compromise the cell viability. This is important when re-
membering that the ﬁrst- and second-generation P-gp inhibitors are
associated with severe toxicity at the concentrations necessary to sig-
niﬁcantly inhibit the P-gp (Potschka, 2012). Moreover, several ﬂavo-
noid preparations are already found on the market as herbal medicines,
or dietary supplements, alleged without nontoxic eﬀects. Indeed, a
variety of ﬂavonoid-containing dietary supplements and herbal pro-
ducts are nowadays marketed for their antioxidant, anticarcinogenic,
anti-inﬂammatory, antiproliferative, antiangiogenic and antiestrogenic
(or estrogenic) eﬀects, with no evidence of toxicity (Bansal et al., 2009;
Ferreira et al., 2015). Additionally, in some animal studies ﬂavonoid
compounds have revealed a weak potential of toxicity. Notwith-
standing, to document the clinical value of these compounds as P-gp
inhibitors capable of reversing the drug-resistant epilepsy requires the
conduction of well-designed clinical trials.
In addition to the identiﬁcation of AEDs or metabolites as P-gp
substrates, the recognition of AEDs as P-gp inducers also highlights the
importance of this strategy to reverse the drug resistance mediated by
P-gp. In fact, the investigated AEDs and their active metabolites in-
duced the P-gp activity (herein assessed by the decrease in intracellular
accumulation of Rh123; Fig. 4). Hence, besides our recognition that all
the AEDs tested, with exception of CBZ-E, had an inducer eﬀect on the
P-gp activity, the existing literature is not extensive regarding these
aspects. In fact, only PHT and CBZ are particularly recognised as P-gp
inducers (Akamine, Miura, Yasui-Furukori, Kojima, & Uno, 2012;
Chhun et al., 2009; Owen, Goldring, Morgan, Park, & Pirmohamed,
2006; U.S. Food and Drug Administration, 2011).
5. Conclusions
In conclusion, ﬁve out of eleven ﬂavonoid compounds tested were
found to increase the intracellular accumulation of Rh123 P-gp probe
substrate in MDCK-MDR1 cells, as well as of AEDs (CBZ, OXC and PHT)
and their active metabolites (CBZ-E and LIC) recognised as substrates of
the P-gp. Hence, these results corroborate that the strategy of co-ad-
ministration of AEDs with safe and potent P-gp inhibitors should con-
tinue to be exploited to reverse the pharmacoresistance in epilepsy, and
ﬂavonoids such as baicalein, (−)-epigallocatechin gallate, kaempferol,
quercetin and particularly silymarin are promising drug candidates to






DMEM Dulbecco's Modiﬁed Eagle's Medium - high glucose
FBS Fetal bovine serum
HPLC High-performance liquid chromatography
LIC Licarbazepine
LTG Lamotrigine
MDCK II Madin-Darby canine kidney cell line
MDCK-MDR1 Madin-Darby canine kidney cell line overexpressing the
human multidrug resistance-1








Conﬂict of interest statement
The authors have declared no conﬂict of interest.
Acknowledgements
The authors are grateful to FCT - Foundation for Science and
Technology (Lisbon, Portugal) for the PhD fellowship of Ana Ferreira
(SFRH/BD/84936/2012). This work was also supported by FEDER
funds through the POCI - COMPETE 2020 - Operational Programme
Competitiveness and Internationalisation in Axis I - Strengthening re-
search, technological development and innovation (Project POCI-01-
0145-FEDER-007491) and National Funds by FCT (Project UID/Multi/
00709/2013).
A. Ferreira et al. Food Research International 103 (2018) 110–120
118
References
Abdallah, H. M., Al-Abd, A. M., El-Dine, R. S., & El-Halawany, A. M. (2015). P-glyco-
protein inhibitors of natural origin as potential tumor chemo-sensitizers: A review.
Journal of Advanced Research, 6(1), 45–62.
Akamine, Y., Miura, M., Yasui-Furukori, N., Kojima, M., & Uno, T. (2012). Carbamazepine
diﬀerentially aﬀects the pharmacokinetics of fexofenadine enantiomers. British
Journal of Clinical Pharmacology, 73(3), 478–481.
Antunes, N., Wichert-Ana, L., Coelho, E. B., Della Pasqua, O., Alexandre Junior, V.,
Takayanagui, O. M., ... Lanchote, V. L. (2016). Inﬂuence of verapamil on the phar-
macokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite
in healthy volunteers. European Journal of Clinical Pharmacology, 72(2), 195–201.
Baluchnejadmojarad, T., Roghani, M., & Homayounfar, H. (2010). Inhibitory eﬀect of
high dose of the ﬂavonoid quercetin on amygdala electrical kindling in rats. Basic
Clinical Neurosciences, 1(3), 57–61.
Bansal, T., Awasthi, A., Jaggi, M., Khar, R. K., & Talegaonkar, S. (2008). Pre-clinical
evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in
combination with quercetin: Possible contribution of P-glycoprotein. Life Sciences,
83(7–8), 250–259.
Bansal, T., Jaggi, M., Khar, R. K., & Talegaonkar, S. (2009). Emerging signiﬁcance of
ﬂavonoids as P-glycoprotein inhibitors in cancer chemotherapy. Journal of
Pharmacy & Pharmaceutical Sciences, 12(1), 46–78.
Barthomeuf, C., Grassi, J., Demeule, M., Fournier, C., Boivin, D., & Béliveau, R. (2005).
Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug
resistance by cnidiadin. Cancer Chemotherapy and Pharmacology, 56(2), 173–181.
Bartmann, H., Fuest, C., la Fougere, C., Xiong, G., Just, T., Schlichtiger, J., ... Potschka, H.
(2010). Imaging of P-glycoprotein-mediated pharmacoresistance in the hippocampus:
Proof-of-concept in a chronic rat model of temporal lobe epilepsy. Epilepsia, 51(9),
1780–1790.
Bauer, B., Hartz, A. M. S., Pekcec, A., Toellner, K., Miller, D. S., & Potschka, H. (2008).
Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through
glutamate and cyclooxygenase-2 signaling. Molecular Pharmacology, 73(5),
1444–1453.
Baulac, M., de Boer, H., Elger, C., Glynn, M., Kälviäinen, R., Little, A., & Ryvlin, P. (2015).
Epilepsy priorities in Europe: A report of the ILAE-IBE epilepsy advocacy Europe task
force. Epilepsia, 56(11), 1687–1695.
Brandt, C., Bethmann, K., Gastens, A. M., & Löscher, W. (2006). The multidrug trans-
porter hypothesis of drug resistance in epilepsy: Proof-of-principle in a rat model of
temporal lobe epilepsy. Neurobiology of Disease, 24(1), 202–211.
Castro, A. F., & Altenberg, G. A. (1997). Inhibition of drug transport by genistein in
multidrug-resistant cells expressing P-glycoprotein. Biochemical Pharmacology, 53(1),
89–93.
Chen, Z., Shi, T., Zhang, L., Zhu, P., Deng, M., Huang, C., ... Li, J. (2016). Mammalian
drug eﬄux transporters of the ATP binding cassette (ABC) family in multidrug re-
sistance: A review of the past decade. Cancer Letters, 370(1), 153–164.
Chhun, S., Verstuyft, C., Rizzo-Padoin, N., Simoneau, G., Becquemont, L., Peretti, I., &
Mouly, S. (2009). Geﬁtinib-phenytoin interaction is not correlated with the C-ery-
thromycin breath test in healthy male volunteers. British Journal of Clinical
Pharmacology, 68(2), 226–237.
Clinckers, R., Smolders, I., Meurs, A., Ebinger, G., & Michotte, Y. (2005). Quantitative in
vivo microdialysis study on the inﬂuence of multidrug transporters on the blood-
brain barrier passage of oxcarbazepine: Concomitant use of hippocampal mono-
amines as pharmacodynamic markers for the anticonvulsant activity. The Journal of
Pharmacology and Experimental Therapeutics, 314(2), 725–731.
Conseil, G., Baubichon-Cortay, H., Dayan, G., Jault, J. M., Barron, D., & Di Pietro, A.
(1998). Flavonoids: A class of modulators with bifunctional interactions at vicinal
ATP- and steroid-binding sites on mouse P-glycoprotein. Proceedings of the National
Academy of Sciences of the United States of America, 95(17), 9831–9836.
Dombrowski, S. M., Desai, S. Y., Marroni, M., Cucullo, L., Goodrich, K., Bingaman, W., ...
Janigro, D. (2001). Overexpression of multiple drug resistance genes in endothelial
cells from patients with refractory epilepsy. Epilepsia, 42(12), 1501–1506.
Ekins, S., Kim, R. B., Leake, B. F., Dantzig, A. H., Schuetz, E. G., Lan, L.-B., & Wrighton, S.
A. (2002). Application of three-dimensional quantitative structure-activity relation-
ships of P-glycoprotein inhibitors and substrates. Molecular Pharmacology, 61(5),
974–981.
Ferreira, A., Pousinho, S., Fortuna, A., Falcão, A., & Alves, G. (2015). Flavonoid com-
pounds as reversal agents of the P-glycoprotein-mediated multidrug resistance:
Biology, chemistry and pharmacology. Phytochemistry Reviews, 14(2), 233–272.
Ferreira, A., Rodrigues, M., Falcão, A., & Alves, G. (2016a). A rapid and sensitive
HPLC–DAD assay to quantify lamotrigine, phenytoin and its main metabolite in
samples of cultured HepaRG cells. Journal of Chromatographic Science, 54(8),
1352–1358.
Ferreira, A., Rodrigues, M., Falcão, A., & Alves, G. (2016b). HPLC–DAD method for the
quantiﬁcation of carbamazepine, oxcarbazepine and their active metabolites in
HepaRG cell culture samples. Chromatographia, 79(9), 581–590.
Ferreira, A., Rodrigues, M., Marques, A., Falcão, A., & Alves, G. (2017). Inﬂuence of the
dual combination of silymarin and (−)-epigallocatechin gallate, natural dietary ﬂa-
vonoids, on the pharmacokinetics of oxcarbazepine in rats. Food and Chemical
Toxicology, 106, 446–454.
Franco, V., French, J. A., & Perucca, E. (2016). Challenges in the clinical development of
new antiepileptic drugs. Pharmacological Research, 103, 95–104.
Freshney, R. I. (2010). Culture of animal cells - a manual of basic technique and specialized
applications (6th ed.). Hoboken, New Jersey: Wiley-Blackwell, Ed.
Gidal, B. E. (2014). P-glycoprotein expression and pharmacoresistant epilepsy: Cause or
consequence? Epilepsy Current, 14(3), 136–138.
Höcht, C., Lazarowski, A., Gonzalez, N. N., Auzmendi, J., Opezzo, J. A. W., Bramuglia, G.
F., ... Girardi, E. (2007). Nimodipine restores the altered hippocampal phenytoin
pharmacokinetics in a refractory epileptic model. Neuroscience Letters, 413(2),
168–172.
Hou, Y., Aboukhatwa, M. A., Lei, D.-L., Manaye, K., Khan, I., & Luo, Y. (2010). Anti-
depressant natural ﬂavonols modulate BDNF and beta amyloid in neurons and hip-
pocampus of double TgAD mice. Neuropharmacology, 58(6), 911–920.
Hoyland, K., Hoy, M., Austin, R., & Wildman, M. (2013). Successful use of haemodialysis
to treat phenobarbital overdose. BMJ Case Reports (pii: bcr2013010011).
Hu, K., Li, S.-Y., Xiao, B., Bi, F., Lu, X.-Q., & Wu, X.-M. (2011). Protective eﬀects of
quercetin against status epilepticus induced hippocampal neuronal injury in rats:
Involvement of X-linked inhibitor of apoptosis protein. Acta Neurologica Belgica,
111(3), 205–212.
Iannetti, P., Spalice, A., & Parisi, P. (2005). Calcium-channel blocker verapamil admin-
istration in prolonged and refractory status epilepticus. Epilepsia, 46(6), 967–969.
Jodoin, J., Demeule, M., & Beliveau, R. (2002). Inhibition of the multidrug resistance P-
glycoprotein activity by green tea polyphenols. Biochimica et Biophysica Acta,
1542(1–3), 149–159.
Jóźwiak, S. (2007). Contemporary opinions on classiﬁcation, pathogenesis and treatment
of drug-resistant epilepsy. Wiadomości Lekarskie, 60(5–6), 258–264.
Knight, J. L., & Weaver, D. F. (1998). A computational quantitative structure-activity
relationship study of carbamate anticonvulsants using quantum pharmacological
methods. Seizure, 7(5), 347–354.
Kwan, P., Li, H. M., Al-Jufairi, E., Abdulla, R., Gonzales, M., Kaye, A. H., & O'Brien, T. J.
(2010). Association between temporal lobe P-glycoprotein expression and seizure
recurrence after surgery for pharmacoresistant temporal lobe epilepsy. Neurobiology
of Disease, 39(2), 192–197.
Liu, X., Yang, Z., Yang, J., & Yang, H. (2007). Increased P-glycoprotein expression and
decreased phenobarbital distribution in the brain of pentylenetetrazole-kindled rats.
Neuropharmacology, 53(5), 657–663.
Löscher, W., Klitgaard, H., Twyman, R. E., & Schmidt, D. (2013). New avenues for anti-
epileptic drug discovery and development. Nature Reviews. Drug Discovery, 12(10),
757–776.
Luna-Tortós, C., Fedrowitz, M., & Löscher, W. (2008). Several major antiepileptic drugs
are substrates for human P-glycoprotein. Neuropharmacology, 55(8), 1364–1375.
Marchi, N., Guiso, G., Caccia, S., Rizzi, M., Gagliardi, B., Noé, F., ... Vezzani, A. (2006).
Determinants of drug brain uptake in a rat model of seizure-associated malformations
of cortical development. Neurobiology of Disease, 24(3), 429–442.
Marchi, N., Hallene, K. L., Kight, K. M., Cucullo, L., Moddel, G., Bingaman, W., & Janigro,
D. (2004). Signiﬁcance of MDR1 and multiple drug resistance in refractory human
epileptic brain. BMC Medicine, 2, 37.
Mohana, S., Ganesan, M., Agilan, B., Karthikeyan, R., Srithar, G., Beaulah Mary, R., ...
Ambudkar, S. V. (2016). Screening dietary ﬂavonoids for the reversal of P-glyco-
protein-mediated multidrug resistance in cancer. Molecular BioSystems, 12(8),
2458–2470.
Nassiri-Asl, M., Hajiali, F., Taghiloo, M., Abbasi, E., Mohseni, F., & Youseﬁ, F. (2014).
Comparison between the eﬀects of quercetin on seizure threshold in acute and
chronic seizure models. Toxicology and Industrial Health, 32(5), 936–944.
Nassiri-Asl, M., Moghbelinejad, S., Abbasi, E., Yonesi, F., Haghighi, M.-R., Lotﬁzadeh, M.,
& Bazahang, P. (2013). Eﬀects of quercetin on oxidative stress and memory retrieval
in kindled rats. Epilepsy & Behavior, 28(2), 151–155.
Nijveldt, R. J., van Nood, E., van Hoorn, D. E., Boelens, P. G., van Norren, K., & van
Leeuwen, P. A. (2001). Flavonoids: A review of probable mechanisms of action and
potential applications. The American Journal of Clinical Nutrition, 74(4), 418–425.
Nishimura, A., Honda, N., Sugioka, N., Takada, K., & Shibata, N. (2008). Evaluation of
carbamazepine pharmacokinetic proﬁles in mice with kainic acid-induced acute
seizures. Biological & Pharmaceutical Bulletin, 31(12), 2302–2308.
Owen, A., Goldring, C., Morgan, P., Park, B. K., & Pirmohamed, M. (2006). Induction of P-
glycoprotein in lymphocytes by carbamazepine and rifampicin: The role of nuclear
hormone response elements. British Journal of Clinical Pharmacology, 62(2), 237–242.
Palmeira, A., Sousa, E., Vasconcelos, M. H., & Pinto, M. M. (2012). Three decades of P-gp
inhibitors: Skimming through several generations and scaﬀolds. Current Medicinal
Chemistry, 19(13), 1946–2025.
Patsalos, P. N., Berry, D. J., Bourgeois, B. F. D., Cloyd, J. C., Glauser, T. A., Johannessen,
S. I., ... Perucca, E. (2008). Antiepileptic drugs-best practice guidelines for ther-
apeutic drug monitoring: A position paper by the subcommission on therapeutic drug
monitoring, ILAE commission on therapeutic strategies. Epilepsia, 49(7), 1239–1276.
Potschka, H. (2012). Role of CNS eﬄux drug transporters in antiepileptic drug delivery:
Overcoming CNS eﬄux drug transport. Advanced Drug Delivery Reviews, 64(10),
943–952.
Raub, T. J. (2006). P-glycoprotein recognition of substrates and circumvention through
rational drug design. Molecular Pharmaceutics, 3(1), 3–25.
Robey, R., Lazarowski, A., & Bates, S. (2008). P-glycoprotein - a clinical target in drug-
refractory epilepsy? Molecular Pharmacology, 73(5), 1343–1346.
Rogawski, M. A. (2013). The intrinsic severity hypothesis of pharmacoresistance to an-
tiepileptic drugs. Epilepsia, 54(Suppl. 2), 33–40.
Romano, B., Pagano, E., Montanaro, V., Fortunato, A. L., Milic, N., & Borrelli, F. (2013).
Novel insights into the pharmacology of ﬂavonoids. Phytotherapy Research, 27(11),
1588–1596.
Schinkel, A. H., & Jonker, J. W. (2012). Mammalian drug eﬄux transporters of the ATP
binding cassette (ABC) family: An overview. Advanced Drug Delivery Reviews, 55(1),
3–29.
Shapiro, A. B., & Ling, V. (1997). Positively cooperative sites for drug transport by P-
glycoprotein with distinct drug speciﬁcities. European Journal of Biochemistry, 250(1),
130–137.
Stouch, T. R., & Gudmundsson, O. (2002). Progress in understanding the structure-
A. Ferreira et al. Food Research International 103 (2018) 110–120
119
activity relationships of P-glycoprotein. Advanced Drug Delivery Reviews, 54(3),
315–328.
Summers, M. A., Moore, J. L., & McAuley, J. W. (2004). Use of verapamil as a potential P-
glycoprotein inhibitor in a patient with refractory epilepsy. The Annals of
Pharmacotherapy, 38(10), 1631–1634.
U.S. Food and Drug Administration. Drug Development and Drug Interactions: Table of
Substrates, Inhibitors and Inducers. (2011). Retrieved from http://www.fda.gov/
Drugs/DevelopmentApprovalProcess/DevelopmentResources/
DrugInteractionsLabeling/ucm093664.htm (Consulted in May 2017).
Ventola, C. L. (2014). Epilepsy management: Newer agents, unmet needs, and future
treatment strategies. P T, 39(11), 776–792.
Wang, E., Barecki-Roach, M., & Johnson, W. W. (2002). Elevation of P-glycoprotein
function by a catechin in green tea. Biochemical and Biophysical Research
Communications, 297(2), 412–418.
Wang, G.-X., Wang, D.-W., Liu, Y., & Ma, Y.-H. (2016). Intractable epilepsy and the P-
glycoprotein hypothesis. The International Journal of Neuroscience, 126(5), 385–392.
Wang, R. B., Kuo, C. L., Lien, L. L., & Lien, E. J. (2003). Structure-activity relationship:
Analyses of p-glycoprotein substrates and inhibitors. Journal of Clinical Pharmacy and
Therapeutics, 28(3), 203–228.
Weiss, J., Kerpen, C. J., Lindenmaier, H., Dormann, S.-M. G., & Haefeli, W. E. (2003).
Interaction of antiepileptic drugs with human P-glycoprotein in vitro. The Journal of
Pharmacology and Experimental Therapeutics, 307(1), 262–267.
Xiong, J., Mao, D.-A., & Liu, L.-Q. (2015). Research progress on the role of ABC trans-
porters in the drug resistance mechanism of intractable epilepsy. BioMed Research
International, 2015, 194541.
Yoon, S. Y., dela Peña, I. C., Shin, C. Y., Son, K. H., Lee, Y. S., Ryu, J. H., ... Ko, K. H.
(2011). Convulsion-related activities of Scutellaria ﬂavones are related to the 5,7-
dihydroxyl structures. European Journal of Pharmacology, 659(2–3), 155–160.
Zhang, C., Kwan, P., Zuo, Z., & Baum, L. (2012). The transport of antiepileptic drugs by P-
glycoprotein. Advanced Drug Delivery Reviews, 64(10), 930–942.
Zhang, C., Zuo, Z., Kwan, P., & Baum, L. (2011). In vitro transport proﬁle of carbama-
zepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by
human P-glycoprotein. Epilepsia, 52(10), 1894–1904.
Zhang, S., & Morris, M. E. (2003a). Eﬀect of the ﬂavonoids biochanin A and silymarin on
the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal
Caco-2 cells. Pharmaceutical Research, 20(8), 1184–1191.
Zhang, S., & Morris, M. E. (2003b). Eﬀects of the ﬂavonoids biochanin A, morin, phlor-
etin, and silymarin on P-glycoprotein-mediated transport. The Journal of
Pharmacology and Experimental Therapeutics, 304(3), 1258–1267.
A. Ferreira et al. Food Research International 103 (2018) 110–120
120
